The problem of toxoplasmosis in outpatient practice. Part III. Toxoplasmosis in pregnants and congenital toxoplasmosis

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Congenital toxoplasmosis is a consequence of acute toxoplasmosis in a pregnant woman. When assessing the risk of сongenital toxoplasmosis during pregnancy, methods for determining specific antibodies, the genetic material of the pathogen (polymerase chain reaction method), immunoglobulins G avidity are used. Molecular genetic methods have the greatest diagnostic value in the diagnosis of сongenital toxoplasmosis in children of the first year of life. Drug prevention of сongenital toxoplasmosis in Russia can be implemented with the use of spiramycin, antenatal therapy is impossible, and postnatal therapy is limited by the list of available antiprotozoal drugs. For the prevention of сongenital toxoplasmosis, the awareness of the population about the ways and factors of transmission of the pathogen is of primary importance.

About the authors

Valerii V. Vasiliev

North-Western State Medical University named after I.I. Mechnikov; Pediatric Research and Clinical Center for Infectious Diseases of Federal Medical and Biological Agency

Email: vcubed@yandex.ru
ORCID iD: 0000-0003-2579-2799

md, dr. sci. (med.), professor

Russian Federation, 41 Kirochnaya St., Saint Petersburg, 191015

Natalia V. Rogozina

Pediatric Research and Clinical Center for Infectious Diseases of Federal Medical and Biological Agency

Email: lelekin96@mail.ru
ORCID iD: 0000-0003-0968-6291

md, cand. sci. (med.), assistant professor

Russian Federation, 197022, Saint-Petersburg, ul. Professora Popova, 9

Regina A. Ivanova

Pediatric Research and Clinical Center for Infectious Diseases of Federal Medical and Biological Agency; Academician I.P. Pavlov First St. Petersburg State Medical University

Author for correspondence.
Email: reg-iv@mail.ru
ORCID iD: 0000-0003-1809-9443

md, cand. sci. (med.), assistant professor

Russian Federation, Saint Petersburg

References

  1. Dubey JP, Murata FHA, Cerqueira-Cézar CK, et al. Congenital toxoplasmosis in humans: an update of worldwide rate of congenital infections. Parasitology. 2021;148(12):1406–1416. doi: 10.1017/S0031182021001013
  2. Milne GC, Webster JP, Walker M. Is the incidence of congenital toxoplasmosis declining? Trends Parasitol. 2023;39(1):26–37. doi: 10.1016/j.pt.2022.10.003.3
  3. Garweg JG, Kieffer F, Mandelbrot L, et al. Long-term outcomes in children with congenital toxoplasmosis — a systematic review. Pathogens. 2022;11(10):1187. doi: 10.3390/pathogens11101187
  4. Melo MS, Cabrera LAA, Lima SVMA, et al. Temporal trend, spatial analysis and spatiotemporal clusters of infant mortality associated with congenital toxoplasmosis in Brazil: Time series from 2000 to 2020. Trop Med Int Health. 2023;28(6):476–485. doi: 10.1111/tmi.13877
  5. Vasiliev VV, Romanova ES. The problem of toxoplasmosis in outpatient practice. Part I. Toxoplasmosis in immunocompromised patients. Russian Family Doctor. 2023;27(1):15–20. (In Russ.) doi: 10.17816/RFD296574
  6. Deganich M, Boudreaux C, Benmerzouga I. Toxoplasmosis infection during pregnancy. Trop Med Infect Dis. 2022;8(1):3. doi: 10.3390/tropicalmed801000
  7. de Barros RAM, Torrecilhas AC, Marciano MAM, et al. Toxoplasmosis in human and animals around the world. Diagnosis and perspectives in the one health approach. Acta Trop. 2022;231:e106432. doi: 10.1016/j.actatropica.2022.106432
  8. Almeria S, Dubey JP. Foodborne transmission of Toxoplasma gondii infection in the last decade. An overview. Res Vet Sci. 2021;135:371–385. doi: 10.1016/j.rvsc.2020.10.019
  9. de Oliveira Azevedo CT, do Brasil PE, Guida L, Lopes Moreira ME. Performance of polymerase chain reaction analysis of the amniotic fluid of pregnant women for diagnosis of congenital toxoplasmosis: a systematic review and meta-analysis. PLoS One. 2016;11(4):e0149938. doi: 10.1371/journal.pone.0149938
  10. Zhou Y, Leahy K, Grose A, et al. Novel paradigm enables accurate monthly gestational screening to prevent congenital toxoplasmosis and more. medRxiv. 2023;2023:04.26.23289132. doi: 10.1101/2023.04.26.23289132
  11. Holec-Gąsior L, Sołowińska K. IgG avidity test as a tool for discrimination between recent and distant toxoplasma gondii infection-current status of studies. Antibodies (Basel). 2022;11(3):52. doi: 10.3390/antib11030052
  12. Wilson RD. Acute perinatal infection and the evidenced-based risk of intrauterine diagnostic testing: a structured review. Fetal Diagn Ther. 2020;47(9):653–664. doi: 10.1159/000508042
  13. Findal G, Helbig A, Haugen G, et al. Management of suspected primary Toxoplasma gondii infection in pregnant women in Norway: twenty years of experience of amniocentesis in a low-prevalence population. BMC Pregnancy Childbirth. 2017;17(1):127. doi: 10.1186/s12884-017-1300-1
  14. Skvarc M. Diagnostic accuracy of adjusted low IgG avidity index to predict acute Toxoplasma gondii infection in the first trimester of pregnancy. Folia Parasitol (Praha). 2022;69:2022.023. doi: 10.14411/fp.2022.023
  15. Mandelbrot L, Kieffer F, Sitta R, et al. Prenatal therapy with pyrimethamine + sulfadiazine vs spiramycin to reduce placental transmission of toxoplasmosis: a multicenter, randomized trial. Am J Obstet Gynecol. 2018;219(4):386.e1–386.e9. doi: 10.1016/j.ajog.2018.05.031
  16. Dunay IR, Gajurel K, Dhakal R, et al. Treatment of toxoplasmosis: historical perspective, animal models, and current clinical practice. Clin Microbiol Rev. 2018;31(4):e00057–17. doi: 10.1128/CMR.00057-17
  17. Prasil P, Sleha R, Kacerovsky M, Bostik P. Comparison of adverse reactions of spiramycin versus pyrimethamine/sulfadiazine treatment of toxoplasmosis in pregnancy: is spiramycin really the drug of choice for unproven infection of the fetus? J Matern Fetal Neonatal Med. 2023;36(1):2215377. doi: 10.1080/14767058.2023.2215377
  18. Paltseva AI, Zverko VL, Sinitsa LN, et al. Congenital toxoplasmosis. Clinical observation. Journal of the Grodno State Medical University. 2020;18(5):611–618. (In Russ.) doi: 10.25298/2221-8785-2020-18-5-611-618
  19. Sotnikov SA, Krjukov EYu, Iova AS, et al. Сlinical report of generalized congenital toxoplasmosis. Journal Infectology. 2014;6(4):87–92. (In Russ.) doi: 10.22625/2072-6732-2014-6-4-87-92
  20. Loh FK, Nathan S, Chow SC, Fang CM. Vaccination challenges and strategies against long-lived Toxoplasma gondii. Vaccine. 2019;37(30):3989–4000. doi: 10.1016/j.vaccine.2019.05.083
  21. Barros M, Teixeira D, Vilanova M, et al. Vaccines in congenital toxoplasmosis: advances and perspectives. Front Immunol. 2021;11:621997. doi: 10.3389/fimmu.2020.621997
  22. El Bissati K, Levigne P, Lykins J, et al. Global initiative for congenital toxoplasmosis: an observational and international comparative clinical analysis. Emerg Microbes Infect. 2018;7(1):165. doi: 10.1038/s41426-018-0164-4

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
 


Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).